Uncategorized

HAMILTON, ON, June 12, 2025 – CPDC, a global leader in the development and commercialization of radiopharmaceuticals, today announced a $650,000 seed investment in RadioSyn Ltd., a Hamilton-based startup company developing a miniaturized automated radiopharmaceutical synthesis device. The shielded synthesizer uses disposable microfluidic chips to perform end-to-end chemical and radiochemical reactions to synthesize radiopharmaceuticals at … Read more

HAMILTON, ON, June 12, 2025 – CPDC and Lab2Market (L2M) today announced the L2M Discover Radiopharma program, a groundbreaking initiative to cultivate entrepreneurial skills among Canadian researchers in the radiopharmaceutical sector. Beginning on September 16, 2025, the 10-week virtual training program will equip students and faculty with the foundational tools necessary to embark on their … Read more

CQDM and the Centre for Probe Development and Commercialization (CPDC) are pleased to announce a strategic initiative  to support the development of next-generation radiopharmaceuticals in Canada. This collaboration represents a unique opportunity to align Canada’s strengths and global expertise in this expanding field. Together we are initiating a collective effort that will foster innovation and growth, and we … Read more

Vancouver, B.C. – December 17, 2024 – The inaugural Symposium on Medical Isotopes, hosted by the Canadian Medical Isotope Ecosystem (CMIE) in partnership with the Canadian Nuclear Isotope Council (CNIC), took place on December 12-13, 2024, at the Holiday Inn & Suites in Vancouver. The event attracted over 70 key stakeholders from across Canada’s medical isotope … Read more

Celebrating our Contribution to Advancing Nuclear Medicine for the World HAMILTON, ON, March 19, 2024 – The Centre for Probe Development and Commercialization (CPDC), a global leader in the development and commercialization of radiopharmaceuticals, is proud to celebrate its 16th anniversary today. Since 2008, CPDC has been at the forefront of advancing nuclear medicine for … Read more

Significant Milestone on the Path to Submission for Canadian Regulatory Approval in Late 2024 HAMILTON, ON, March 13, 2024 – The Centre for Probe Development and Commercialization (CPDC), a global leader in the development and commercialization of radiopharmaceuticals, today announced the closure of the Canadian Phase 3 trial for [18F]PSMA-1007. [18F]PSMA-1007 is a positron-emitting tomography … Read more

HAMILTON, ON, July 29, 2024 – The Centre for Probe Development and Commercialization (CPDC), a global leader in radiopharmaceutical development and commercialization, today announced that its Founder, John Valliant, Ph.D., has stepped down from its Board of Directors. Dr. Valliant established CPDC in 2008 as a Centre of Excellence for the Commercialization of Research in … Read more

HAMILTON, ON and TORONTO, ON, July 6, 2023 – The Centre for Probe Development and Commercialization (CPDC) is pleased to announce a collaboration with Dr. Neil Vasdev at the Centre for Addiction and Mental Health (CAMH) to develop a novel positron emission tomography (PET) tracer specific for the activin receptor-like kinase 2 (ALK2) protein. Under … Read more

HAMILTON, ON and VANCOUVER, BC, July 4, 2023 – The Centre for Probe Development and Commercialization (CPDC) is proud to announce its funding of a new research project led by Dr. Robert Britton at Simon Fraser University (SFU) aimed at developing a novel positron emission tomography (PET) tracer that targets the L-type amino acid transporter … Read more

The Canadian Medical Isotope Ecosystem will support the development, production, advancement and distribution of isotopes, and position Canada as an international medical isotope powerhouse VANCOUVER, BC, and HAMILTON, ON, June 27, 2023 — The Centre for Probe Development and Commercialization (CPDC) and TRIUMF Innovations today announced they will receive up to $35 million in funding for … Read more